Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

BACKGROUND: Middle East respiratory syndrome (MERS) coronavirus causes a highly fatal lower-respiratory tract infection. There are as yet no licensed MERS vaccines or therapeutics. This study (WRAIR-2274) assessed the safety, tolerability, and immunogenicity of the GLS-5300 MERS coronavirus DNA vacc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Infect Dis
Main Authors: Modjarrad, Kayvon, Roberts, Christine C, Mills, Kristin T, Castellano, Amy R, Paolino, Kristopher, Muthumani, Kar, Reuschel, Emma L, Robb, Merlin L, Racine, Trina, Oh, Myoung-don, Lamarre, Claude, Zaidi, Faraz I, Boyer, Jean, Kudchodkar, Sagar B, Jeong, Moonsup, Darden, Janice M, Park, Young K, Scott, Paul T, Remigio, Celine, Parikh, Ajay P, Wise, Megan C, Patel, Ami, Duperret, Elizabeth K, Kim, Kevin Y, Choi, Hyeree, White, Scott, Bagarazzi, Mark, May, Jeanine M, Kane, Deborah, Lee, Hyojin, Kobinger, Gary, Michael, Nelson L, Weiner, David B, Thomas, Stephen J, Maslow, Joel N
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Ltd. 2019
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185789/
https://ncbi.nlm.nih.gov/pubmed/31351922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(19)30266-X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados